Maybe the previous loss had something to do with the start up of the Royal Adelaide contract? I imagine that is now a pretty low friction lucrative recurring revenue stream. Id say the 6 months to June 2018 and YTD performance would be more relevant for valuation purposes. Also, I imagine if a larger organisation bought the infusion business, they wouldnt need any of our infusions staff so generate savings...
$64 question is, who is in the business of buying small infusion businesses?
Maybe the previous loss had something to do with the start up of...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.20 |
Change
0.200(1.11%) |
Mkt cap ! $349.8M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.20 | $17.65 | $78.15K | 4.366K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 619 | $17.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.20 | 146 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |